Cargando…
Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
BACKGROUND: OnabotulinumtoxinA 20 U reduces glabellar line (GL) severity at maximum frown for approximately 3 to 4 months. Small studies have suggested that >20-U doses may increase the efficacy and duration of response for GLs. OBJECTIVES: The aim of this study was to evaluate safety, pharmacody...
Autores principales: | Joseph, John H, Maas, Corey, Palm, Melanie D, Lain, Edward, Glaser, Dee Anna, Bruce, Suzanne, Yoelin, Steven, Cox, Sue Ellen, Fagien, Steven, Sangha, Sara, Maltman, John, Lei, Xiaofang, Brin, Mitchell F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558451/ https://www.ncbi.nlm.nih.gov/pubmed/35704394 http://dx.doi.org/10.1093/asj/sjac157 |
Ejemplares similares
-
Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles
por: Carruthers, Alastair, et al.
Publicado: (2016) -
Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Carruthers, Jean, et al.
Publicado: (2023) -
PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data
por: Solish, Nowell, et al.
Publicado: (2022) -
Submental Area Treatment with ATX-101: Relationship of Mechanism of Action, Tissue Response, and Efficacy
por: Humphrey, Shannon, et al.
Publicado: (2022) -
OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Review
por: De Boulle, Koenraad, et al.
Publicado: (2020)